For the roughly 1.6 million Americans living with type 1 diabetes, the daily calculus of insulin injections, continuous glucose monitors, and the ever-present threat of dangerous blood sugar crashes has been the only reality. Now a small clinical trial is challenging that reality in a way the field has pursued for decades: coaxing the body to make its own insulin again.
Vertex Pharmaceuticals disclosed in its 2025 annual report filed with the U.S. Securities and Exchange Commission that all 12 participants who received its investigational stem cell therapy, VX-880 (zamislecel), began producing endogenous insulin. The company said it is working toward submitting a biologics license application (BLA) to the U.S. Food and Drug Administration in 2026, a move that would make VX-880 one of the first stem cell-derived therapies for type 1 diabetes to seek full regulatory approval.
What VX-880 does and who it is for
Type 1 diabetes is an autoimmune disease in which the immune system destroys the pancreatic beta cells responsible for producing insulin. Without those cells, patients depend on externally delivered insulin for survival. VX-880 aims to reverse that loss by infusing laboratory-grown, stem cell-derived beta cells into the patient’s body, where they can take up residence and begin secreting insulin in response to blood sugar levels.
The ongoing Phase 1/2 trial, registered with the National Institutes of Health under identifier NCT04786262, is enrolling adults with type 1 diabetes who have impaired awareness of hypoglycemia or a history of severe hypoglycemic episodes. These are patients at the sharpest end of the disease, people for whom even advanced insulin pumps and continuous glucose monitors often fail to prevent life-threatening lows. The study’s primary endpoints focus on safety and tolerability, with secondary measures tracking insulin production (via C-peptide, a biomarker released when the body makes its own insulin) and glycemic control.
What the data show so far
Vertex’s SEC filing states that 12 participants who received VX-880 began producing their own insulin. The company has also presented patient-level data at scientific conferences, including the American Diabetes Association’s annual meetings in 2023 and 2024, where researchers reported measurable C-peptide levels, reductions in daily insulin requirements, and improvements in HbA1c (a marker of long-term blood sugar control) in treated patients.
Those conference presentations offered encouraging snapshots, but they covered a small number of patients followed for varying lengths of time. Detailed, peer-reviewed publication of the full dataset has not yet appeared, which means independent researchers have not had the opportunity to scrutinize the methodology, examine patient-level outcomes, or assess how consistently the therapy performed across different individuals.
Still, the results are notable in context. The only previously approved cell therapy for type 1 diabetes is donislecel (Lantidra), which the FDA cleared in 2023. Donislecel relies on insulin-producing cells harvested from deceased human donors, a process that severely limits supply. VX-880’s use of stem cell-derived cells could, in theory, remove that bottleneck and make cell-replacement therapy available to far more patients.
The immunosuppression trade-off
One significant caveat accompanies VX-880: because the infused cells come from a donor-derived stem cell line rather than the patient’s own body, recipients must take chronic immunosuppressive drugs to prevent their immune systems from rejecting the transplant. Long-term immunosuppression carries well-documented risks, including heightened vulnerability to infections, increased cancer risk, and potential kidney or liver toxicity.
For patients already enduring severe, unpredictable hypoglycemia, that trade-off may be acceptable. For the broader type 1 diabetes population, it is a harder sell. Vertex appears to recognize this. The company is also developing VX-264, a separate program that encapsulates the same stem cell-derived beta cells inside a protective device designed to shield them from the immune system, potentially eliminating the need for immunosuppression altogether. VX-264 is in earlier-stage testing, and its results will be closely watched as a next-generation approach.
Regulatory pathway and what comes next
VX-880 holds Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, a status the agency reserves for regenerative medicine products targeting serious or life-threatening conditions when preliminary clinical evidence suggests they may address unmet medical needs. According to the FDA’s RMAT guidance, the designation can provide more frequent interactions with agency reviewers, potential eligibility for priority review, and the possibility of accelerated approval based on surrogate endpoints such as C-peptide production.
Importantly, RMAT designation does not lower the bar for approval. Vertex must still demonstrate that VX-880’s benefits outweigh its risks through data the FDA considers adequate. The company’s 10-K filing explicitly notes that its 2026 BLA submission target is subject to manufacturing challenges, evolving regulatory expectations, new safety findings, and competition from other therapies. Any of those factors could delay the timeline.
If Vertex does file the BLA on schedule, the FDA review process would likely include an advisory committee meeting where outside experts publicly debate the therapy’s merits, followed by a formal approval decision.
What patients with severe hypoglycemia should discuss with their doctors
For the millions of people managing type 1 diabetes, VX-880’s progress is a meaningful signal that restoring the body’s own insulin production is biologically achievable, not just theoretical. But the therapy remains in clinical research, and its practical implications are currently limited to trial participants.
Patients with type 1 diabetes who experience severe hypoglycemia or impaired hypoglycemia awareness and are interested in cell-based therapies should talk with their endocrinologist about eligibility for ongoing studies. The conversation should include a frank discussion of what chronic immunosuppression entails and how it compares to the risks they already face.
The milestones that will determine whether VX-880 moves from promising experiment to available treatment are now relatively well defined: peer-reviewed publication of the full clinical dataset, formal BLA submission to the FDA, and the agency’s subsequent review. Alongside those steps, the broader question looming over the field is whether next-generation approaches like VX-264 can deliver the same beta-cell restoration without requiring patients to suppress their immune systems for life. The answer to that question could determine whether cell therapy for type 1 diabetes remains a niche option for the sickest patients or becomes a transformative treatment for the disease as a whole.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
